Loading clinical trials...

Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans | Clinical Trials | Clareo Health

COMPLETEDNA

Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans

Effect of a Glucagon Like Peptide 1 (GLP1) Booster on Blood Glucose, HbA1c, Insulin, and GLP1 Levels, Body Weight and Body Fat in Overweight Adult Men and Women

NCT06333496•Alpine Biotech LLC

View on ClinicalTrials.gov

Summary

BACKGROUND GLP1 booster (GB) was designed to stimulate the endogenous production of GLP1, which in turn releases insulin, controls blood glucose level, suppresses appetite and thus helps people lose weight. PURPOSE The purpose of this study is to assess several clinical endpoints and questionnaires in healthy volunteers taking the new GB formula. SCOPE The scope of this protocol covers the non-clinical portion as well as the assessment of several clinical endpoints and questionnaires. In brief, the non-clinical design will be an open-label study involving volunteers taking GB everyday for 12 weeks. Data analysis will involve measuring the clinical endpoints across the group at different timepoints.

Eligibility

Age

18 - 65 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•Volunteers must be over the age of 18.
•Volunteers cannot be smokers.
•Volunteers cannot be currently taking a dietary supplement or prescription for weight loss.
•Exercising volunteers must maintain their regimen consistently throughout the course of the 12-week study.
•Caffeine drinking volunteers must maintain their caffeine intake consistently throughout the course of the 12-week study.
•Volunteers need to be overweight but not obese, as defined by having a BMI between 25.0 and 29.9

Exclusion Criteria

•Female volunteers who are pregnant or planning to become pregnant within the next three months.
•Volunteers who are taking any stimulant medications (e.g. Adderall, Adzenys, Dexedrine, Ritalin, Methylphenidate, etc).

Locations (1)

Alpine Bio

Salt Lake City, Utah, United States

Key Dates

Start Date

January 2, 2024

Primary Completion Date

March 29, 2024

Completion Date

May 8, 2024

Last Updated

December 5, 2024

Enrollment

ACTUAL participants

Conditions

Blood Sugar; HighOverweight and ObesityFat BurnObesityHeart Health Markers

Interventions

GLP-1 Booster (GB)

DIETARY_SUPPLEMENT

Nutrition Care in Patients Living With Chronic Pain

NCT06277232

Nutrition PoorOverweight and Obesity+2 more

View study

RECRUITINGNA

The Effects of a 4-week Supplementation With a Ketogenic Nutrient Mix on 24-hour Substrate Metabolism and Muscle Health

NCT07395973

Overweight and Obesity

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: December 5, 2024Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effect of a Glucagon Like Peptide 1 (GLP1) Booster in Healthy Humans

Inclusion Criteria

Exclusion Criteria

Nutrition Care in Patients Living With Chronic Pain

The Effects of a 4-week Supplementation With a Ketogenic Nutrient Mix on 24-hour Substrate Metabolism and Muscle Health

Social Determinants and a Diabetes Prevention Program Tailored for African Americans

Becoming United in Lifestyle Decisions

Effect of GLP1 Receptor Agonist on Brain Insulin Responsiveness

Protein Digestion After Bariatric Surgery in Older Adults